Delivery Order SPE2DB20D3101-SPE2DB22FH7T9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,748.21 to AmerisourceBergen Drug Corp for RELPAX 20 mg tablets (unit dose, 6-count packaging) on January 12, 2026, with an ultimate completion date of January 13, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award is a child delivery order issued under AmerisourceBergen Drug Corp's parent company...
- The Defense Logistics Agency issued a $18,762.91 delivery order to AmerisourceBergen Drug Corp on February 24, 2026, for RELPAX 40 mg tablet UD 6s pharmaceutical supply. Place of performance is Conshohocken, PA 19428. Ultimate completion date is February 25, 2026. The order carries a firm fixed price structure and was issued without set-aside. The parent vehicle is an Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999 through December 2026, supporting global...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,419.27 firm fixed-price delivery order is for the supply of eletriptan HBR 20 mg tablets. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $6,051.71 delivery order contract is for the supply of Eletriptan HBr 40 mg tablets. The contract has a firm-fixed price pricing type and an ultimate completion date of September 19, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product eletriptan hydrobromide 40 mg tablets. The $1,617.17 fixed-price delivery order was placed by the Defense Logistics Agency (DLA), a defense agency of the U.S. government. Amerisourcebergen, a major pharmaceutical distributor, holds a single-award Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop Support Medical through 2025. This...
- This federal contract award, valued at $16,865.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order to provide UBRELVY 100 MG TABLET UD 16S, a specialty pharmaceutical product. The contract has an ultimate completion date of October 18, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of 4,564,478,636 units of the pharmaceutical product Eletriptan HBR 40 mg tablets. The contract, valued at $1,116.08, is a firm fixed-price delivery order placed by the Defense Logistics Agency (DLA), a defense agency within the Department of Defense. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) valued up to...
- This federal contract award, valued at $1,712.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of zolmitriptan 5 mg tablets and has a completion date of November 19, 2024. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999...
- This federal contract award, valued at $1,845.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The contract covers the delivery of a range of pharmaceutical products and medical supplies,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $17,435.75 firm fixed price delivery order is for the supply of the drug Almotriptan Malate 6.25 mg tablets, with a completion date of February 10, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB22FH7T9Delivery Order
This federal contract award, valued at $1,814.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of 4556217978 RELPAX 40 MG TABLET UD 6S, with an ultimate completion date of February 10, 2022. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 2/9/22 |